This event has an open abstract session.
Abstracts can be submitted on any subject related to Alzheimer’s Disease
The Deadline for abstract submissions for oral presentation is March 10th 2015
Abstracts for poster presentation only can be submitted up to two weeks before the event
You can download the instructions for authors at
www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf
The Deadline for abstract submissions for oral presentation is March 10th 2015
Abstracts for poster presentation only can be submitted up to two weeks before the event
EVENT DETAIL
23 June 2015 – 23 June 2015
LONDON, UK
This three day event will discuss aspects of Alzheimer’s Disease development and treatment in an informal academic setting. Topics for discussion include prediction and prevention strategies, vaccine development, drug discovery and care. With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking regarding Alzheimer’s Disease.
Dr Frank O. Bastian, MD, Professor of Animal Science, LSU Agricultural center, Baton Rouge, LA & Professor of Pathology, Tulane Medical School, New Orleans, LA, US
Eye movement biomarkers in Alzheimer’s disease,
Dr Olivier Coubard, The Neuropsychological Laboratory, Paris, France
Oral Inflammation, Tooth Loss, Risk Factors, and Association with Progression of Alzheimer’s Disease
Dr Sim K. Singhrao Oral & Dental Sciences Research Group, School of Medicine & Dentistry, University of Central Lancashire, Preston, UK
Novel Retinal Microvascular Network and Retinal Ganglion Cell Imaging in Alzheimer’s Disease
Dr Carol Y Cheung, PhD, Research Scientist, Singapore Eye Research Institute, Singapore Eye Research Institute, The Academia, 20 College Road, Discovery Tower Level 6, Singapore
Interspecies comparative gene expression profiling revealed energy failure as the results of impaired insulin production and insulin signaling in Alzheimer’s disease brains: The Hisayama Study.
Dr Yusaku Nakabeppu, DVM, D.Sc. Distinguished Professor and Director of Research Center for Nucleotide Pool, Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
Development of allosteric activators of the Trk receptors for neuroprotection in AD
Dr Nicholas Webster, Ph.D., M.A., Professor of Medicine, Chief, Division of Endocrinology and Metabolism, Associate Director for Shared Resources, Moores Cancer Center, University of California, San Diego, USA
Driving quality care for people with dementia in nursing homes: The impact of large scale inter-professional student clinical placements.
Dr Andrew Robinson RN, MNS, PhD, Professor of Aged Care Nursing, School Of Health Sciences., Co-Director, Wicking Dementia Research and Education Centre., University of Tasmania, Hobart, Tasmania, Australia
ACAT1/SOAT1 as a therapeutic target for treating AD
Dr Ta Yuan Chang, PhD, Professor, Department of Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, NH, USA
Reduction in Antipsychotic Medication Use Among US Nursing Home Residents: Regulation Revisions and a National Partnership
Professor Jane Mort, Pharm.D., Associate Dean for Academic Programs, Professor of Pharmacy Practice, College of Pharmacy, South Dakota State University, USA
Modulation of mitochondrial dynamics as an early AD (MCI) therapy
Dr Shirley ShiDu Yan, MD, Distinguished Professor, Chief of Division of Neuroscience and Neurodegenerative diseases, Higuchi Bioscience Center, University of Kansas, Lawrence, USA
The link between beta-amyloid and tau in disrupting synaptic function
Professor Alain Buisson, Neuroscience, Université Joseph Fourier Grenoble, La Tronche, France
Virus infection and Alzheimer clinical progression
Professor Federico Licastro, MD, Professor of Immunology, Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of Bologna, Italy
Associate Professor Carmela Matrone, Ph.D., Dept. of Biomedicine, Aarhus University, Aarhus, Denmark
Eye-drops of G-CSF Gene Ameliorate Brain Function in Preclincal Neurological Disorder
Dr Philip Liu, PhD, Associate Biologist and Associate Professor of Radiology, Mass General Hospital and Harvard Medical School, Charlestown, MA, USA
Various phenotypes of Alzheimer’s disease and management strategies
Dr Chuang-Kuo Wu, M.D., Ph.D., FANA, Director, Alzheimer’s Disease Program, Texas Tech University Health Sciences Center, School of Medicine, Lubbock, Texas, USA
Loss of Tau function impairs autophagic amyloid clearance: the potential of autophagy-inducing cancer drugs for AD treatment
Assistant Professor Charbel Moussa, MD, PhD, Georgetown University Medical Center, Washington DC, USA
5-HT4 receptor agonists and multi-target directed ligands : novel promising agents for prevention of Alzheimer’s disease
Dr Sylvie Claeysen, PhD, HDR, Institut de Génomique Fonctionnelle, Université de Montpellier, Montpellier, France
The ER-based acetylation machinery and its impact in Alzheimer’s disease
Dr Luigi Puglielli, M.D., Ph.D., Associate Professor Department of Medicine, University of Wisconsin-Madison, Madison VA Hospital (GRECC 11G), Madison, WI, USA
Cell cycle dysregulation in Alzheimer’s disease lymphocytes: a mirror of pathogenesis and diagnostic prospects
Professor Urszula Wojda, Head of the Laboratory of Advanced Preclinical Research Neurobiology Center, Nencki Institute of Experimental Biology, Warsaw, Poland
Reasons for high rates of dementia in Australia’s Indigenous population.
Assistant Professor Robert Parker, James Cook University Townsville Queensland Australia, Casuarina, NT, Australia
Extracellular chaperones: the garbage clearance system you can’t live without
Professor Mark R Wilson, School of Biological Sciences, Faculty of Science, Medicine & Health, University of Wollongong, Wollongong, Australia
Brazil nuts improve selenium status and cognitive performance in mild cognitive impairment elderly
Dr Bárbara Rita Cardoso, University of São Paulo, Campinas, São Paulo, Brazil
The U.S. National Alzheimer’s Coordinating Center (NACC)—freely available standardized, clinical and neuropathological data on > 30,000 subjects from NIH funded AD centers—potential for research and replication.
Dr Walter A. Kukull, PhD, Professor of Epidemiology, Director, National Alzheimer’s Coord Ctr (NACC), University of Wash., Dept of Epidemiology, Seattle, WA, USA
Online information about the prevention of Alzheimer’s Disease: The good, the bad, and the ugly
Dr. Julie Robillard, University of British Columbia, Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada
Treatment of Alzheimer with novel biologics
Dr Mourad Tayebi, Surrey University, Guildford, Surrey, UK
Diagnosis of mild cognitive disorders in older adults: the usefulness of evaluation of Activities of Daily Living
Prof. Dr. Patricia De Vriendt, Vrije Universiteit Brussel, Jette & Artevelde University College Ghent, Belgium
Carergiver distress in dementia
Ms Kaye Ervin, University of Melbourne, Vic, Australia
Diabetes and Alzheimer Disease: Imaging mechanisms accelerating cognitive decline in diabetes”
Assistant Professor Myria Petrou MA MBChB MS, Department of Radiology, Division of Neuroradiology, University of Michigan, Michigan, USA
Beta-amyloid aggregation inhibitors and the treatment of Alzheimer’s disease, focussing on our retro-inverso peptide and nanoparticle-based approaches
Professor David Allsop, Professor of Neuroscience, Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, United Kingdom
